Clarivate Alternatives for Life Sciences: What to Evaluate in 2026

When Clarivate announced it was exploring a sale of its Life Sciences & Healthcare division in February 2026, a lot of commercial and BD leaders had the same reaction: Now what?

Not panic — more like a permission slip. Many life sciences teams have been quietly frustrated with the cost, complexity, and rigidity of legacy intelligence platforms for years. A potential ownership transition is the catalyst that turns "we should probably evaluate alternatives" into "we need to evaluate alternatives now."

But the alternatives landscape for life sciences is not straightforward. Clarivate's LS&HC division is not one product — it is a bundle of products serving different buyers with different needs. Cortellis serves R&D and regulatory affairs. DRG Fusion serves market access and commercial strategy. BioWorld serves competitive intelligence. The 300+ person consulting team serves everyone.

Replacing Clarivate is not a single decision. It is three or four decisions depending on which parts of the portfolio you actually use. This guide breaks down the alternatives by use case so you can make those decisions with clarity.

The Starting Point: What Are You Actually Paying For?

Before evaluating alternatives, start with an honest audit. In our conversations with life sciences commercial teams, a consistent pattern emerges: companies subscribe to enterprise bundles but heavily use only a subset of features.

Here are the questions worth answering before you talk to any vendor:

Which Clarivate products does your team use daily? Not which ones are on the contract — which ones does someone actually log into every day? For many BD and sales teams, the answer is "Cortellis once a week for a specific pipeline query" and "BioWorld for headlines." That is a very different need than the regulatory affairs team running structured queries across 80+ jurisdictions.

What is your cost per insight? Clarivate contracts typically run six figures annually. If your BD team's primary use case is preparing for meetings and tracking account activity, you may be paying $100,000+ for what is fundamentally an expensive research interface.

How much of the data is proprietary vs. publicly available? This is the critical question. Clarivate has genuinely proprietary data — analyst-annotated drug pipeline metadata, patient-level claims data, structured regulatory filings. But a significant portion of what commercial teams use (news, earnings data, clinical trial status, leadership changes, press releases) is publicly available. AI-native platforms now synthesize that public data faster and at a fraction of the cost.

What is the switching cost — really? Many teams overestimate switching costs because they conflate "we use Clarivate" with "we need Clarivate." Separating R&D needs from commercial needs often reveals that the switching cost for BD and sales teams is surprisingly low.

The Two Categories of Clarivate Alternatives

The biggest mistake teams make when evaluating Clarivate alternatives is treating it as a single replacement decision. In practice, the alternatives break into two distinct categories based on what you need.

Category 1: Proprietary Data Platforms (R&D and Regulatory)

If your primary need is structured drug pipeline databases, curated regulatory intelligence, or patient-level real-world data, you are looking at platforms that have invested decades in building proprietary datasets. These are not cheap, and they are not fast to implement — but they solve problems that AI cannot solve from public data alone.

Citeline (Norstella) is the most direct Cortellis replacement. Their TrialTrove database covers 60,000+ sources of clinical trial data with deep proprietary curation. They recently launched Ella, an AI assistant for natural-language pipeline queries. Expect enterprise pricing in the six-figure range, similar to Clarivate.

GlobalData provides the broadest market coverage — 290+ datasets spanning pharma, medtech, insurance, and adjacent sectors. Their strength is breadth. If you need a single platform that covers multiple industries beyond life sciences, GlobalData is worth evaluating. Pricing typically falls in the $30K–$80K+/year range.

When to choose Category 1: Your regulatory affairs team needs structured filings across jurisdictions. Your R&D team needs analyst-annotated pipeline metadata. Your market access team needs patient-level claims data. These are genuine proprietary data needs that require specialized providers.

Category 2: AI-Native Intelligence Platforms (Commercial and BD)

If your primary need is account research, buying signals, meeting preparation, and commercial prospecting, you are looking at a newer category of platforms that use AI to synthesize publicly available data into actionable intelligence. These are faster to deploy, dramatically cheaper, and increasingly more useful for daily selling workflows.

AlphaSense sits between the two categories. It offers AI-powered search across 500M+ documents, including expert call transcripts and broker research. It is strong for competitive intelligence teams that need deep document research. Pricing ranges from $10K to $100K+/year depending on the modules and team size.

Zymewire is purpose-built for CROs, CDMOs, and contract service organizations selling into pharma. Their 120+ signal facets are specifically designed for life sciences sales prospecting, with human-verified curation on top of automated monitoring. Pricing typically runs $15K–$40K+/year.

Salesmotion takes a different approach entirely. Rather than building proprietary databases, Salesmotion uses AI to monitor and synthesize intelligence from over 1,000 public sources — clinical trial registries, earnings calls, news, press releases, leadership changes, job postings, and more — into account briefs with AI-generated talking points. It scans and consolidates clinical trial data globally from ClinicalTrials.gov and public registries. Setup takes 20 minutes, not weeks. Pricing starts at $85/month for individuals and $990/month for teams with unlimited users. For a detailed feature breakdown, see the full Clarivate vs Salesmotion comparison.

When to choose Category 2: Your BD and sales teams need to research accounts quickly, track trigger events across their territory, and personalize outreach. They do not need proprietary regulatory filings — they need context, signals, and talking points.

“Salesmotion is helping Cytel elevate our enterprise sales performance by embedding account intelligence directly into our workflow. The platform gives our commercial team real-time visibility into key account movements.”

Jonathan Burr

Chief Commercial Officer, Cytel

Read case study →

Head-to-Head Comparison

Here is how the five main alternatives stack up across the factors that matter most:

The key insight from this table: there is no single Clarivate replacement. The right answer depends on which buying persona you are solving for. Many teams will end up with a Category 1 platform for R&D and a Category 2 platform for commercial — and still spend less than their current Clarivate contract.

What Life Sciences Teams Actually Need Day-to-Day

Theory is useful. What does this look like in practice for a BD rep at a CRO, a sales manager at a CDMO, or a commercial strategy lead at a biotech?

Here is the daily workflow that most commercial teams are trying to solve:

Morning: Check what changed overnight across key accounts. New clinical trial filings, earnings releases, leadership changes, M&A news, press releases about strategic priorities. Legacy platforms require logging into multiple tools and manually searching each account.

Before a meeting: Build a briefing document with account context — recent news, financial performance, strategic priorities, clinical pipeline activity, competitive landscape, and talking points relevant to the conversation. On legacy platforms, this takes 45–90 minutes of research across multiple sources.

During prospecting: Identify which accounts in a territory are showing buying signals right now — budget approvals, new clinical programs, team expansions, vendor reviews, regulatory milestones. Legacy platforms are not designed for this kind of real-time, cross-account signal monitoring.

Weekly planning: Prioritize accounts based on signal density and engagement opportunity, not just pipeline stage or last-touch date. This requires aggregated signal data across the territory, not account-by-account lookups.

These workflows are where AI-native platforms have a structural advantage. They are designed for speed, synthesis, and cross-account visibility — not for deep proprietary data queries.

“We had a variety of tools, and that was the pain — the variety. We had to go to multiple places to get streamlined data.”

Lyndsay Thomson

Head of Sales Operations, Cytel

Read case study →

Proof Point: How Cytel Evaluated and Switched

Cytel is a 2,000+ employee life sciences analytics company headquartered in Cambridge, MA, founded in 1987. Their commercial team sells biostatistical consulting, clinical trial design, and regulatory strategy to pharma and biotech sponsors worldwide.

Before evaluating alternatives, Cytel's sales team was juggling 5+ research tools to prepare for meetings, plan accounts, and execute outreach. The fragmentation created three problems: time wasted toggling between tools, inconsistent research quality across reps, and slow ramp time for new hires.

After evaluating the landscape, Cytel implemented Salesmotion and saw measurable results:

• 50% reduction in account research time — reps get synthesized account briefs instead of building them manually
• 5-to-1 tool consolidation — one platform replaced five separate research and intelligence tools
• 30% reduction in account planning prep time — AI-generated talking points and account summaries accelerated weekly planning

The implementation itself was notably fast. Cytel's Head of Sales Operations, Lyndsay Thomson, compared it directly to other vendor experiences: "All of the vendors that I've worked with... Salesmotion was the easiest." The platform was live and delivering value within the first day — not weeks or months.

For the full story, including how Cytel's enterprise selling motion changed with signal-driven intelligence, read the Cytel case study.

The Evaluation Framework: 5 Questions Before You Choose

If you are actively evaluating Clarivate alternatives, here is a practical decision framework. Run through these five questions with your team before scheduling vendor demos.

1. Separate R&D needs from commercial needs

This is the single most important step. Your regulatory affairs team and your BD team have fundamentally different requirements. The regulatory team needs structured, proprietary, curated data. The BD team needs speed, signals, and synthesis. Trying to solve both with one platform usually means overpaying for one group and underserving the other.

2. Quantify your current cost per use case

Break your Clarivate contract down by business unit and estimated usage. If your BD team accounts for 30% of the contract value but could be served by a $990/month platform, the math becomes clear quickly. If your R&D team accounts for 70% and genuinely needs proprietary pipeline data, you know where to focus your enterprise evaluation.

3. Test the 80/20 hypothesis

For commercial use cases, can an AI-native platform deliver 80–90% of the account intelligence your BD team needs at a fraction of the cost? The way to test this is simple: run a two-week trial alongside your current tools. Give your reps access to both and measure which one they actually use for daily workflows. At Salesmotion, the trial takes 20 minutes to set up.

4. Evaluate signal coverage, not just data depth

Legacy platforms emphasize data depth — how many compounds in the database, how many regulatory filings indexed. For commercial teams, what matters is signal breadth: how many types of buying signals does the platform track, how quickly do alerts fire, and how well does the platform synthesize signals into actionable context? A platform that monitors 1,000+ sources in real time is often more valuable for BD than a platform with a deeper but narrower proprietary dataset.

5. Factor in the ownership transition timeline

If you are a current Clarivate customer, your contract will be honored through its term regardless of who buys the LS&HC division. But renewals are where risk concentrates. New owners — especially PE firms — frequently adjust pricing, consolidate products, and shift roadmaps. Evaluating alternatives now, before your next renewal, gives you leverage regardless of what happens with the sale.

What Happens Next with the Clarivate Sale

As of March 2026, Clarivate has appointed Morgan Stanley as financial advisor and says it is in "active discussions with interested parties." The company has not named potential buyers or disclosed a timeline.

The likely buyer profiles include:

• Private equity firms — the life sciences data space has attracted significant PE interest. A PE buyer would likely focus on margin optimization, which historically means price increases and product consolidation for customers.
• Strategic acquirers like IQVIA or Norstella — either could fold Clarivate's LS&HC products into their existing portfolios. This would create a larger but potentially more consolidated market.
• Technology companies — a less likely but possible scenario where a tech company acquires the division for its data assets and customer relationships.

For current customers, the practical implication is the same regardless of buyer: the 6–12 months around an ownership transition are the highest-risk period for pricing changes, roadmap shifts, and support disruptions. Teams that evaluate alternatives proactively have more leverage and more options than teams that wait.

For a deeper analysis of the sale itself and its broader market implications, read the full breakdown: Clarivate Is Selling Its Life Sciences Business — What It Means for Sales Teams.

Key Takeaways

• Clarivate's LS&HC division ($389.8M revenue, declining 6.9% YoY) is being explored for sale — creating a natural evaluation moment for current customers
• There is no single Clarivate replacement. Separate R&D/regulatory needs (Citeline, GlobalData) from commercial/BD needs (AlphaSense, Zymewire, Salesmotion)
• For commercial teams, the critical question is how much of your Clarivate usage relies on proprietary curated data vs. publicly available intelligence wrapped in an expensive interface
• Cytel, a 2,000+ employee life sciences company, consolidated 5 tools into Salesmotion, cutting account research time by 50% and account planning prep by 30%
• AI-native platforms offer 20-minute setup, real-time signal monitoring, and pricing starting at $85/month — vs. six-figure annual contracts and weeks-long implementations
• Evaluate alternatives before your next renewal, not after the ownership transition creates pricing uncertainty

Related Pages

• Top 5 Clarivate Alternatives for Life Sciences Teams — full comparison with feature matrix
• Clarivate vs Salesmotion — Full Comparison
• Clarivate Is Selling Its Life Sciences Business — original news analysis
• How Cytel Cut Sales Research Time by 50% — life sciences case study
• Sales Intelligence for Life Sciences
• Sales Intelligence for Pharma
• Sales Intelligence for Clinical Research (CROs)
• Signal-Based Selling Framework — how buying signals drive BD workflows

Frequently Asked Questions

What is the best Clarivate alternative for life sciences R&D teams?

For R&D and regulatory affairs teams that need proprietary drug pipeline data, structured regulatory filings, and curated compound databases, Citeline (Norstella) is the most direct replacement. Their TrialTrove database covers 60,000+ sources with deep proprietary curation, and their Ella AI assistant enables natural-language pipeline queries. Expect enterprise pricing similar to Clarivate (six figures annually). GlobalData is another option if your team needs broader market coverage beyond just drug pipelines, typically at a lower price point ($30K–$80K+/year).

What is the best Clarivate alternative for life sciences sales and BD teams?

For BD and commercial teams focused on account research, meeting prep, and prospecting, the answer depends on your sales motion. Salesmotion offers the broadest signal coverage (1,000+ sources) and lowest price point (from $85/month) with 20-minute setup — ideal for teams that need account intelligence without six-figure contracts. Zymewire is purpose-built for CROs, CDMOs, and contract service organizations with 120+ signal facets specifically designed for life sciences sales prospecting ($15K–$40K+/year). AlphaSense serves competitive intelligence teams that need deep document search across 500M+ documents ($10K–$100K+/year).

Will my Clarivate contract still be honored if the LS&HC division is sold?

Yes. Existing contracts will be honored regardless of ownership change. However, the risk concentrates at renewal time. New owners — particularly private equity firms — frequently adjust pricing, consolidate products, and shift product roadmaps. The 6–12 months around an ownership transition are historically the highest-risk period for contract terms to change. Evaluating alternatives before your next renewal gives you leverage.

Can AI-native platforms replace Clarivate's proprietary data?

Not entirely — and that is the wrong framing. Clarivate has genuinely proprietary data that AI cannot replicate from public sources: analyst-annotated drug pipeline metadata, patient-level claims data, and structured regulatory filings across 80+ jurisdictions. But for commercial and BD teams, the relevant question is what percentage of your daily usage relies on that proprietary data vs. publicly available intelligence. Many BD teams discover that 80–90% of their account research needs can be served by AI platforms that synthesize public data — clinical trial registries, earnings calls, news, leadership changes — at a fraction of the cost. Platforms like Salesmotion actively scan and consolidate clinical trial data globally from ClinicalTrials.gov and public registries, alongside 1,000+ other sources.

How long does it take to switch from Clarivate to an alternative?

It depends on the category. Enterprise proprietary data platforms (Citeline, GlobalData) typically require weeks of onboarding, data migration, and training — similar to the original Clarivate implementation. AI-native platforms are dramatically faster. Salesmotion takes 20 minutes to set up and delivers value from day one — Cytel's team described it as the easiest vendor onboarding they had experienced. The practical approach is to run a parallel evaluation: keep your Clarivate subscription active through its current term while testing alternatives. This eliminates switching risk and gives you real usage data to inform your renewal decision.